Clinical trials in Reims – page 7

421 clinical trials in Reims, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Reims at a glance

421

clinical trials

Research sites1

Quick filters

421 trials in Reims

Open in trial search

K-ras gene mutation+1

Recruiting

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

B-cell small lymphocytic lymphoma refractory+1

Recruiting

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:BeOne Medicines AG

Contact Research Centre

Transitional cell carcinoma

Recruiting

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Triple negative breast cancer

Recruiting

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease+1

Recruiting

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

Registered drugNo placebo

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Sarcoma+4

Recruiting

Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer

InvestigationalNo placebo

Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Zanidatamab
Sponsor:Unicancer

Contact Research Centre

Neoplasm

Recruiting

Study on the Safety and Effects of EIK1004 for Patients with Advanced Solid Tumors

InvestigationalNo placebo

Study on the Safety and Effects of EIK1004 for Patients with Advanced Solid Tumors

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Sponsor:Eikon Therapeutics Inc.

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Janssen Cilag International

Contact Research Centre

Renal transplant

Recruiting

Study of Belatacept versus Tacrolimus in Kidney Transplant Recipients with Subclinical Antibody Mediated Rejection

Registered drugNo placebo

Study of Belatacept versus Tacrolimus in Kidney Transplant Recipients with Subclinical Antibody Mediated Rejection

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Belatacept
Sponsor:Centre Hospitalier Universitaire Rouen

Contact Research Centre

Urethral valves

Recruiting

Study on the Effectiveness and Safety of Circumcision and Antibiotic Treatment (Cefaclor, Sulfamethoxazole, Trimethoprim) for Boys with Posterior Urethral Valves

Registered drugNo placebo

Study on the Effectiveness and Safety of Circumcision and Antibiotic Treatment (Cefaclor, Sulfamethoxazole, Trimethoprim) for Boys with Posterior Urethral Valves

Registered drugNo placebo

France

Participants:0–17 years
Substances:Amoxicillin
Sponsor:Centre Hospitalier Universitaire De Bordeaux

Contact Research Centre

Pancreatic carcinoma

Recruiting

Study on Chemotherapy for Patients with Resected Pancreatic Cancer Using FOLFIRINOX and Drug Combination

Registered drugNo placebo

Study on Chemotherapy for Patients with Resected Pancreatic Cancer Using FOLFIRINOX and Drug Combination

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Centre Hospitalier Universitaire Rouen

Contact Research Centre

Adenocarcinoma pancreas

Recruiting

Study on Optimizing NALIRIFOX and 5-FU for Metastatic Pancreatic Cancer in First-Line Treatment and Exploring Ciprofloxacin in Second-Line Therapy

Registered drug

Study on Optimizing NALIRIFOX and 5-FU for Metastatic Pancreatic Cancer in First-Line Treatment and Exploring Ciprofloxacin in Second-Line Therapy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Ciprofloxacin
Sponsor:Association Gercor

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Reims

What the registry says about research in the country

01 Oncology Studies

Groundbreaking research exploring treatments for various cancers, including multiple myeloma, colorectal cancer, and esophageal squamous cell carcinoma. Studies focus on evaluating novel therapies and combination treatments to improve patient outcomes.

Advanced pancreatic adenocarcinoma treatments
Breast cancer therapies
Prostate cancer management

Several trials investigate immunotherapy approaches and targeted treatments for specific genetic mutations.

02 Autoimmune Conditions

Clinical trials examining innovative treatments for autoimmune disorders, with particular focus on rheumatoid arthritis and psoriatic conditions. Research aims to evaluate new therapeutic approaches and optimize existing treatments.

Plaque psoriasis treatments
Rheumatoid arthritis maintenance therapy
Gout management strategies

Studies emphasize long-term efficacy and safety profiles of various treatment regimens.

03 Transplant Medicine

Advanced research in kidney transplantation focusing on preventing rejection and improving long-term outcomes. Studies evaluate new immunosuppressive strategies and monitoring protocols.

Antibody-mediated rejection prevention
Novel immunosuppressive protocols
Post-transplant monitoring techniques

Trials aim to optimize post-transplant care and reduce rejection rates.

Back to France All countries